Finance entity
Weiss Ratings is the most frequent co-covered peer, appearing in 17 of the 20 tracked stories. Negative sentiment reaches 0% here, compared with 17% across the 595-story beat baseline for the same window. Coverage clusters in markets, which accounts for 13 of those 20, with the remainder spread across 1 other category.
Last mentioned: 4d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Weiss Ratings is the most frequent co-covered peer, appearing in 17 of the 20 tracked stories. Negative sentiment reaches 0% here, compared with 17% across the 595-story beat baseline for the same window. Coverage clusters in markets, which accounts for 13 of those 20, with the remainder spread across 1 other category. The 30-day window averages about 4.7 stories each week. The busiest single day carried 4. At 5, the average consequence score sits below the same-window beat average of 5.7. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. This profile follows 20 Finance stories mentioning Wall Street Zen across the period from August 11, 2026 to September 9, 2026.
Computed from the 20 stories linked to this entity, with beat comparisons drawn from all 595 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Wall Street Zen. Shared-story counts are live from our verified record — not editorial picks.
Eaton Shares Rise 2.8%
Shares trade as high as $430.25 and last at $422.2780, closing above the 50-day and 200-day moving averages.
Dividend payment
The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
Morgan Stanley and Weiss Ratings Turn Constructive
Morgan Stanley raises its Eaton target to $520 from $500 and Weiss Ratings upgrades the stock from hold to buy.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Ex-dividend date
Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
Wall Street Zen upgrades both stocks
Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
Friday trading close
AMPY opened at $4.78 and BRSP opened at $5.00.
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Benchmark and Weiss update AMPY
Benchmark cut the AMPY target to $9.00 from $11.00 with a buy rating; Weiss raised AMPY from sell(d) to sell(d+).
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Citigroup lifts KVYO target
Citigroup raised its Klaviyo price target from $34.00 to $36.00 with a Buy rating.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
KVYO analyst revisions
Stephens, BTIG, Stifel, and Truist adjusted price targets on Klaviyo following earnings.
ZVIA reports Q2 results
Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
Klaviyo Q2 earnings
Klaviyo reported EPS of $0.19, meeting consensus, and revenue of $370.58 million.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
Douglas Emmett reports earnings
Douglas Emmett reported quarterly EPS of negative $0.02.
A Sunday morning research note lifted Wall Street Zen's view on two biotechs—argenx to buy and Tenaya from strong sell to sell—but the market implications diverge sharply. Finance readers get a comparison of a profitable $63 billion rare-disease leader trading at a 38.67 P/E against a $148.75 million speculative gene therapy name at -1.25 P/E.
Eaton's 2.8% climb to $422.28 reflects a cluster of price-target raises led by Morgan Stanley and RBC. For finance readers, the key tension is a 20-analyst Buy consensus versus a 42.96 P/E and 2.60 PEG that price in significant electrification growth.
Source: tickerreport.com · dailypolitical.com
Needham & Company reiterated Buy ratings on Salesforce (CRM) and Solaris Energy Infrastructure (SEI) with price targets of $400 and $98. CRM opened at $259.39, implying 54% upside, while SEI opened at $55.08, implying 78% upside. The ratings highlight divergent risk-reward profiles across software and energy infrastructure.
Source: tickerreport.com · dailypolitical.com
Hollencrest Capital Management nearly exited UNH in Q2 2026, but much larger institutions piled in. Analysts remain bullish with price targets up to $490. For finance readers, the 13F reveals a rotation in shares rather than a fundamental warning.
Source: Ticker Report · Daily Political
A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Source: dailypolitical.com · tickerreport.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Replimune missed consensus EPS by $0.03 but held near its 52-week high at $14.97. Insider sales totaling over $650,000 were tax-related, while analyst targets now range up to $17, creating a gap between the $11.86 average target and the stock price.
Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Safe Pro Group reported a quarterly EPS of -$0.15, one cent below consensus, but shares soared 37.7% on 21x average volume. The move pushed market cap to $128.89M even as negative net margin widened to 800.91%.
Source: MarketBeat · themarketsdaily.com
Wall Street Zen downgraded both Oceaneering International and Klaviyo from Buy to Hold, spotlighting two $5 billion market-cap companies with vastly different P/E ratios—14.59 for OII and 895.95 for KVYO. The ratings actions come as consensus targets diverge from current prices.
Source: dailypolitical.com · themarketsdaily.com
Wall Street Zen cut Stag Industrial to sell, putting a fresh bearish tilt on a REIT whose shares opened at $36.68 versus a $50.50 consensus target. The same firm also downgraded Zevia PBC as its major shareholder trimmed a 15.87% stake.
Source: tickerreport.com · dailypolitical.com
Seneca Foods posted a top-line beat of $405.17M, 24% above estimates, despite a $0.07 EPS miss, driving a 7.4% stock surge and Strong Buy ratings. Talkspace, meanwhile, missed on both EPS and revenue, but its stock held steady as institutional investors continued accumulating shares.
Source: themarketsdaily.com · dailypolitical.com
Verra Mobility shares plunged 12% on August 8, 2026, despite beating Q2 earnings estimates. Analyst consensus is 'Reduce' with a $7 target, while Vistance Networks also gapped down amid mixed signals including a $5 dividend and institutional buying.
Source: themarketsdaily.com · tickerreport.com
ESCO Technologies lifted its full‑year EPS forecast above analyst estimates, signaling strong margin expansion. Q4 guidance brackets consensus while management’s confidence is backed by a Q3 beat and a spotless balance sheet. With a consensus Buy rating and $410 average target, the raised outlook may fuel further estimate revisions.
Source: tickerreport.com · dailypolitical.com
USANA Health Sciences stunned the Street with fiscal 2026 earnings guidance of just $0.76 per share, 64% below consensus, and revenue of $910 million—following a quarterly loss of $0.07. With analyst consensus dropping to Reduce and the stock trading near its 52-week low, investors are reassessing valuation and downside risk.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen’s hold upgrade caps a series of mixed analyst actions on Talphera, whose stock trades at $1.41 despite a $3.00 average target. Institutional positioning and a technical breakout suggest the market may be repricing a depressed small-cap. For investors, the gap represents both a unique opportunity and a cautionary tale of biotech volatility.
Wall Street Zen is linked from 44 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
